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Background/aim: Recent data draw attention to the effect of body composition, insulin resistance, and adipocytokines to acne vulgaris
(AV) development. The aim of this study was to assess the association of AV with insulin resistance and adipocytokine levels and to
evaluate the effect of isotretinoin on insulin resistance and adipocytokine levels.
Materials and methods: In 29 AV patients and 29 healthy volunteers, body mass index (BMI) and body fat mass (BFM), lipid,
adiponectin, leptin, resistin, retinol binding protein-4 (RBP4), and insulin levels were measured and insulin resistance was assessed by
HOMA-IR index in serum samples taken twice from patients before and after isotretinoin treatment.
Results: In AV patients, pretreatment HOMA-IR and adipocytokine levels were not found to correlate with disease severity. With five
months of isotretinoin treatment, higher HOMA-IR values were found (P = 0.028). Isotretinoin therapy maintained lower mean resistin
levels (P = 0.016), higher mean RBP4 levels (P = 0.040), but not affected the mean adiponectin and leptin levels (P = 0.113, P = 0.125,
respectively).
Conclusions: All data suggests that five months of isotretinoin therapy in AV patients causes insulin resistance and the increase in insulin resistance is not dependent on age, BMI, BFM, and lipid levels of these patients.
Key words: Acne vulgaris, adipocytokine, insulin sensitivity

1. Introduction
Acne vulgaris (AV) is a chronic inflammatory
multifactorial disease of the pilosebase unit that
affects 85% of the population aged 12–24 years (1–4).
Characteristic lesions are comedones, inflammatory
papules, pustules, and nodules and cysts that can lead to
scarring and pigmentation changes (1). AV pathogenesis
is multifactorial. Abnormal follicular keratinization,
increased production of sebum, Propionibacterium acnes
(P. acnes) colonization and inflammation are implicated
(1).
13-cis-retinoic acid (isotretinoin) is a vitamin A
(retinol) metabolite that has been used for about 30
years in nodulocystic and other treatment-resistant AV
treatment (5). The mechanism of action of isotretinoin, a
turning point in AV treatment, is not fully known.
Vitamin A and its metabolites play a complex role in the
regulation of insulin sensitivity. While some retinoic acid

isomers cause an increase in insulin sensitivity through
peroxisome proliferator activating receptors (PPARs),
isotretinoin increases the level of total cholesterol and
triglyceride and decreases the level of high-density
lipoprotein (HDL), resulting in an insulin resistance-like
condition (6,7). Controversial results have been obtained
about the subject in different studies (8,9).
Recent studies have shown that fat tissue is not only an
energy-storing organ, but also has endocrinological and
immunological functions. Bioactive mediators secreted by
adipose tissue are called adipocytokines (10).
We aimed to evaluate the association of insulin
resistance and adipocytokine levels with disease in patients
with AV, to explain the metabolic and antiinflammatory
effects of isotretinoin treatment on adipocytes, and to
evaluate the effects of adipocytokines on insulin resistance
development and inflammatory processes during and after
isotretinoin treatment.
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2. Materials and methods
2.1. Study group
Twenty-nine patients diagnosed with AV who were older
than 18 years of age and had clinical severity of stage II
and above were included. The control group consisted of
29 healthy volunteers who did not have any inflammatory
skin disease and whose mean age and sex matched with
those of the patient group.
People with pregnancy, lactation, hyperlipidemia, liver
or renal dysfunction, a systemic disease such as diabetes,
atherosclerotic heart disease, thyroid disease, anemia, and
metabolic disease were not included in the study. Those
with hypervitaminosis, psychiatric disease, muscle disease,
and a history of isotretinoin hypersensitivity were not
included in the study either. Those who used drugs that
interact with isotretinoin such as vitamin A, tetracycline,
minocycline were also excluded. Patients with excessive
side effects due to current treatment during the treatment
period and those without complete remission at the end of
the treatment were also excluded from the study.
At the beginning of the study, local ethics committee
approval was obtained and a written consent form was
obtained from all volunteers stating that they were
informed about the study.
2.2. Methods
Patients with stage I-IVAV that were refractory to other
treatments were included in the study and were treated
with isotretinoin at a dose of 0.5 mg/kg/day. Acne severity
of patients was determined by clinical staging method;
stage I: comedonal acne, stage II: mild papulopustular
acne, stage III: severe papulopustular acne, stage IV:
nodulocytic acne.
In order to perform body composition analysis, a
device of TANITA TBF 300 model based on bioimpedance
principle was used.
For serum levels of leptin, resistin, retinol binding
protein-4 (RBP4), and insuline, samples were taken from
the antecubital region in the morning on an empty stomach
after 10–12 h fasting once in the control group and before
and after treatment in the patient group. LDL cholesterol,
total cholesterol, triglyceride, HDL cholesterol, and fasting
blood glucose levels were evaluated and HOMA-IR index
(glucose X insulin / 405) was calculated. Body weight,
body mass index (BMI), and body fat percentage values
were also recorded simultaneously.
Leptin, resistin, adiponectin, and RBP4 were
evaluated quantitatively by ELISA in serum samples.
In the leptin assay, the DIAsource leptin ELISA (catalog
no. KAP2281), the adiponectin assay BioVendor human
adiponectin ELISA (catalog no. RD191023100), the
resistin assay BioVendor human resistin ELISA (catalog
no. RD191016100), and the RBP4 Immunodiagnostik

ELISA (K6110) prepared kits were used. At the end of
the study, the optical densities formed on the plates were
evaluated spectrophotometrically by a 450 nm automated
ELISA reader.
2.3. Statistical analysis
The analysis of the data was done in SPSS for Windows
11.5 package program. The Kolmogorov–Smirnov test was
used to determine whether the distribution of continuous
and intermittent variables was appropriate for normal
distribution. The significance of differences between
the groups in terms of mean values 
was determined
using the Student’s t-test. The significance of the median
values was examined using the Mann–Whitney U test.
Nominal variables were assessed using the Pearson’s chisquare test. The significance of the difference between the
pretreatment and posttreatment clinical measures in the
study group in terms of the mean values was assessed using
the Wilcoxon sign test, which is significant in terms of
median values with the dependent t-test. Whether there is
a statistically significant relationship between continuous
and intermittent numerical variables was examined using
the Spearman’s correlation test. The results for all P < 0.05
were considered statistically significant unless otherwise
stated.
3. Results
In our study, there were 29 AV patients with 14 (48.3%)
female and 15 (51.7%) male AV patients and 16 (55.2%)
female and 13 (44.8%) male patients in the control
group. There were no statistically significant differences
concerning age (P = 0.599) and ratio of the sex (P = 0.131).
Acne severity in patients was stage II in 2 (6.9%), stage III
in 23 (79.3%), and stage IV in 4 (13.8%) patients (Table 1).
3.1. Pretreatment evaluation
There was no statistically significant difference between
the patient group and the control group in terms of the
mean BMI (P = 0.780), body fat mass (BFM) (P = 0.829),
total cholesterol, LDL cholesterol, HDL cholesterol
Table 1. The demographic and clinical findings of our study
population.
Parameters

Study group

Control group

P-value

Age (year)

20.5 ± 1.9

21.4 ± 2.5

0.131†

Female

14 (48.3)

16 (55.2)

0.599‡

Male

15 (51.7)

13 (44.8)

Sex (n (%))

Stage (n (%))

-

II

2 (6.9)

-

III

23 (79.3)

-

IV

4 (13.8)

-
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and triglyceride levels before treatment. There were no
statistically significant difference between the patient and
control groups in terms of median HOMA-IR index (P =
0.182), leptin (P = 0.683), adiponectin (P = 0.978), resistin
(P = 0.515), and RBP4 (P = 0.681) levels (Table 2).
There was no significant correlation between disease stage
and HOMA, leptin, adiponectin, resistin, and RBP4 levels
in the study group (P > 0.05).
3.2. Pretreatment vs. posttreatment comparison
When clinical measurements of patients were evaluated
before and after treatment, there was no statistically
significant difference in terms of BMI (P = 0.477) and
mean body fat mass (P = 0.685). There was a statistically
significant increase in mean total cholesterol (P < 0.001),

LDL cholesterol (P = 0.002), and triglyceride (P = 0.009),
and a statistically significant decrease in HDL cholesterol
(P = 0.0028).
Isotretinoin treatment did not affect the median leptin
(P = 0.125) and adiponectin (P = 0.113) levels, while a
statistically significant increase in median HOMA-IR
index was observed after treatment (P = 0.028). There was
a statistically significant decrease in median resistin (P =
0.016) and median RBP4 (P = 0.040) after treatment (Table
3).
In the present study, there was no statistically
significant correlation between age, basal BMI, body fat
mass, and lipid levels and the amounts of HOMA, leptin,
adiponectin, resistin, and RBP4 after treatment (P > 0.025).

Table 2. The results of biochemical parameters in our study population.
Parameters

Study group

Control group

P-value

BMI

22.1 ± 2.6

21.9 ± 2.7

0.780†

Body fat mass (kg)

11.7 ± 4.4

11.4 ± 5.0

0.829†

Total cholesterol (mg/dL)

169.0 ± 33.2

162.8 ± 42.7

0.550†

LDL cholesterol (mg/dL)

103.8 (66.0–174.0)

93.8 (49.2–171.8)

0.400‡

HDL cholesterol (mg/dL)

45.5 (33.0–83.0)

48.0 (32.0–79.0)

0.704‡

Trigliserid (mg/dL)

68.0 (40.0–219.0)

81.0 (38.0–296.0)

0.277‡

HOMA

1.55 (0.58–3.64)

1.43 (0.46–2.75)

0.182‡

Leptin (ng/mL)

1.82 (0.67–9.02)

1.82 (0.30–7.31)

0.683‡

Adiponectin (μg/mL)

12.4 ± 4.36

12.4 ± 4.0

0.978†

Resistin (ng/mL)

10.1 (5.7–20.1)

10.8 (5.0–26.3)

0.515‡

RBP4 (mg/L)

30.7 ± 9.1

32.0 ± 13.9

0.681†

Table 3. The effect of the 5-month treatment of isotretinoin on BMI, body fat mass,
cholesterol, adiponectin, resistin, and RBP4 levels in AV patients.

240

Parameters

Pretreatment

BMI

21.9 ± 2.7

Posttreatment
21.8 ± 2.5

P-value
0.477

Body fat mass (kg)

11.4 ± 5.0

11.3 ± 4.4

0.685

Total cholesterol (mg/dL)

162.8 ± 42.7

187.4 ± 51.3

<0.001

LDL cholesterol (mg/dL)

93.8 (49.2–171.8)

122.4 (47.8–189.0)

0.002

HDL cholesterol(mg/dL)

48.0 (32.0–79.0)

44.0 (28.0–73.0)

0.028

Triglyceride (mg/dL)

81.0 (38.0–296.0)

117.0 (47.0–310.0)

0.009

HOMA-IR

1.43 (0.46–2.75)

1.54 (0.57–4.40)

0.028

Leptin (ng/mL)

1.82 (0.30–7.31)

1.93 (0.60–5.04)

0.125

Adiponectin (μg/mL)

12.4 ± 4.0

13.3 ± 4.7

0.113

Resistin (ng/mL)

10.8 (5.0–26.3)

7.1 (5.2–23.9)

0.016

RBP4 (mg/L)

32.0 ± 13.9

36.4 ± 15.8

0.040
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4. Discussion
Isotretinoin is a vitamin A (retinol) metabolite that has been
used for about 30 years in AV treatment (5), but there are
few studies addressing the metabolic effects of isotretinoin
on humans. Our study showed that isotretinoin treatment
resulted in 1) a statistically significant decrease in the
mean HDL cholesterol level, 2) increased total cholesterol,
LDL cholesterol, and triglyceride levels, 3) increased
HOMA-IR value, 4) decreased the mean resistin level, 5)
increased the mean RBP4, 6) did not affect the mean leptin
level, and 7) no statistically significant correlation between
age, pre-treatment BMI, body fat mass, and lipid levels and
the amount of change in RBP4 level. These data suggest
that isotretinoin therapy causes an increase in insulin
resistance independent of differences in age, BMI, body
fat, and lipid levels in AV patients.
In our study, in accordance with the literature (8,11–13),
total cholesterol, LDL cholesterol, triglyceride levels, and
mean HDL cholesterol levels decreased with isotretinoin
treatment. Pre- HOMA-IR values that were not different
from those of the control group were increased significantly
after treatment (P = 0.028) (Table 3). Vitamin A and its
metabolites play a complex role in the regulation of insulin

sensitivity. While some retinoic acid isomers cause an
increase in insulin sensitivity through PPARs, isotretinoin,
a vitamin A derivative, cause an insulin resistance-like
condition (7). Studies evaluating the effects of retinoid
therapy on insulin resistance and glucose metabolism in
the literature have yielded different results (6–9,14,15)
(Table 4). Koistinen et al. using a hyperinsulinemiceuglycemic clamp technique, found that insulin sensitivity
was reduced in 11 patients treated with isotretinoin for 5
months and that a condition similar to insulin resistance
syndrome developed with isotretinoin (8). Using the same
method, the same group also showed a decrease in insulin
sensitivity (7). Heliövaara et al. evaluated insulin resistance
by oral glucose tolerance test and reported that isotretinoin
causes impaired glucose tolerance (6). In the literature,
there have been reports of insulin-dependent diabetes
mellitus developed after isotretinoin treatment (16, 17).
Corbetta et al. reported a temporary and mild decrease in
insulin sensitivity assessed by HOMA-IR in all 10 patients
treated with acitretin for only a month (18). These studies,
although not explaining the molecular mechanism of this
effect, point out that oral isotretinoin affects and reduces
insulin sensitivity (6–8), suggesting that isotretinoin may

Table 4. The studies about the effect of isotretinoin on insulin metabolism.
Study

Year Patient number Retinoid

Koistinen et al. (8)

2001 11M

Ertuğrul et al. (9)

2011 48 (35F,13M)

Stoll et al. (14)

2004 15M

Koistinen et al. (7)

2006 11M

Corbetta et al. (18) 2006 10M

Heliövaara et al. (6) 2007 23 (11F, 12M)

Karadag et al. (15)

Our study

2015 33 (18F, 15M)

29 (14F, 15M)

Time

Results
Insulin sensitivity↓
Isotretinoin 5th month
( hyperinsulinemic-euglycemic clamp)
Insulin sensitivity↔
Isotretinoin 3rd month
(HOMA-IR)
Insulin sensitivity↔
Isotretinoin 5th day
(HOMA-IR)
Insulin sensitivity↓
Isotretinoin 5th month
(hyperinsulinemic-euglycemic clamp)
Adiponectin↑
Insulin sensitivity↓
(HOMA-IR)
Asitretin
1st and 3rd month
Adiponectin↔
Resistin↓
Insulin sensitivity↓
Isotretinoin 3rd month
(Oral glucose tolerance test)
Adiponectin↑
Insulin sensitivity↔
(HOMA-IR)
Isotretinoin 3rd month
Adiponectin↑
Leptin↑
RBP4↔
Insulin sensitivity↓
(HOMA-IR)
Adiponectin↔
Isotretinoin 5th month
Leptin↔
Resistin↓
RBP4↑
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be related to the transcription of various metabolic genes
via RAR and RXR (8,19). There are also reports stating that
isotretinoin does not affect insulin sensitivity (9,14,15).
Ertuğrul et al. (9) in 48 patients and Karadag et al. (15) in
33 patients did not observe a change in HOMA-IR value in
the third month of isotretinoin treatment.
The results of our study showed that isotretinoin
treatment caused an increase in insulin resistance
independent of changes in age, BMI, body fat, and lipid
levels. The lack of correlation between the increase in lipids
and HOMA-IR suggests that the insulin resistance in our
AV patients has developed through a different mechanism.
Recent studies have shown that fat tissue is not only an
energy-storing organ, but also has endocrinological and
immunological functions. Bioactive mediators secreted by
adipose tissue are called adipocytokines (10). Adiponectin,
pre-B cell enhancing factor/ visfatin, leptin, RBP4, TNF-α,
IL-6, MCP-1, monocyte chemotactic protein-1, and IL-1
are among these adipokines (20). Adiponectin is the most
abundant adipocyte in the circulation. This adipocytokine,
which increases insulin sensitivity, is also thought to have
antiinflammatory effects. Serum concentrations have
been shown to decrease in conditions that lead to insulin
resistance. Serum level of this cytokine, which is inversely
related to BMI, is considered a marker of systemic insulin
sensitivity (21).
It has been suggested that isotretinoin causes an
insulin resistance-like condition in AV patients (6–8).
Adiponectin levels were evaluated before and after
treatment in patients treated with isotretinoin, considering
that adiponectin is a marker of insulin sensitivity and
an antiinflammatory cytokine in our study. In our study,
the mean of posttreatment adiponectin levels measured
was higher than that of the pretreatment levels, but the
difference was not statistically significant (P = 0.113)
(Table 3). The literature shows conflicting results about
this issue (Table 4). Koistinen et al. evaluated insulin
resistance and adiponectin levels in patients prior to
treatment, at the 5th month of treatment, and 1 month
after termination of treatment, and similar to our study,
they found a 34% increase in adiponectin levels compared
with the decrease in insulin sensitivity in patients during
treatment. In this study, it was suggested that increased
adiponectin level despite presence of an insulin resistance
may be a physiological adaptation mechanism against
insulin resistance (7). Similarly, in a study conducted
by Heliövaara et al. (6) with 27 AV patients, it was
suggested that isotretinoin increases insulin resistance
in patients, paradoxically also increases adiponectin
levels and regulates inflammatory parameters. The
paradoxical increase of adiponectin was attributed to the
antiinflammatory effect of retinoids in the study (6).
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Karadag et al. (15) showed that adiponectin levels
increased statistically compared to the pretreatment
levels in the third month of treatment with isotretinoin
in patients with AV, without any evidence of insulin
resistance. Transcription of PPARγ coassociated with RXR
is increased by treatment with isotretinoin (22). PPARγ
has been reported to increase adiponectin gene expression
(23). Thus, it has been suggested in a study that prolonged
13-cis retinoic acid treatment may lead to an increase in
adiponectin levels by increasing PPARγ transcription
(22). Aydin et al. found that basal adiponectin levels of
18 female patients with severe acne were significantly
lower than those of the the controls and after 6 months
of treatment with isotretinoin, basal adiponectin levels
significantly increased without insulin resistance. They
revealed increased adiponectin response to oral glucose
tolerance test at 2 h in acne patients but this effect was lost
after isotretinoin treatment. In this study, it was suggested
that isotretinoin treatment restores dysregulation of
adiponectin dynamics in severe acne (24).
Contrary to these studies, Zhang et al. showed
that a single dose of retinoic acid caused a decrease in
adiponectin mRNA levels in adipose tissue of rats (25).
Different retinoid derivatives have probably different
effects on adiponectin metabolism. Cisneros et al. did not
detect any changes in serum adiponectin and leptin levels
in rats given low-dose isotretinoin and all-trans-retinoic
acid for seven days (5). Mcllroy et al. reported a decrease
in adipose tissue adiponectin mRNA levels following a
high-fat diet in rats and that this reduction was returned to
normal again after treatment with fenretinide, a synthetic
retinoid (26). Corbetta et al. reported that there was no
change in adiponectin levels in patients with psoriasis
while there was a slight decrease in insulin sensitivity and
a decrease in resistin levels after one month of treatment
with acitretin (18).
In the light of these data, a decrease in the adiponectin
level was expected in the case of insulin resistance,
whereas an increase adiponectin level was observed
after isotretinoin treatment in our study, though it was
not statistically significant. This can be attributed to the
reduction of inflammation by treatment, as noted in
similar studies in the literature (23,25).
In our study, isotretinoin treatment increased the mean
leptin level but the difference was not enough to produce a
statistically significant effect (P = 0.125) (Table 3). Leptin
is a cytokine-like hormone which is a gene product of
obese (ob) and is mostly synthesized by subcutaneous
adipose tissue. The level correlates with the amount of
BMI and adipose tissue (21). The main task of leptin is to
regulate body weight and appetite (27). For this reason,
this cytokine is closely related to insulin and glucose
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metabolism. Leptin has also proinflammatory effects
and is involved in natural and acquired immunity. In the
literature, inhibition of leptin secretion has been shown to
be induced by retinoic acid derivatives in animal studies
in which retinoic acid derivatives other than isotretinoin
were used. In our study, no change in leptin levels after
long-term isotretinoin denies any effect of isotretinoin on
leptin levels in AV patients.
Resistin is an adiponectin produced by adipocytes,
adipose tissue monocytes, macrophages, and peripheral
blood monocytes. In addition to their role in adipogenesis,
inflammation, and cardiovascular disease, many studies
(21,28,29), but not all (30,31), show increased levels of
plasma/tissue in obesity and diseases associated with
insulin resistance. In our study, isotretinoin treatment for
5 months reduced the mean resistin level (P = 0.016) in
29 AV patients (Table 3). On the other hand, there was
no correlation between the stage of the disease and the
pretreatment and postreatment resistin levels and there
was no statistically significant correlation between age,
pre-treatment BMI, body fat mass, and lipid levels and the
amount of change in resistin level with treatment. Felipe
et al. suggested that thiazolidinediones in the antidiabetic
drug group, which have inhibitor effect on the resistin
gene, act through PPARgamma and that PPARgamma
coexists with RXR; thus, retinoic acid may affect resistin
expression. In the study, it was reported that resistin
expression in rats that were given 9-cis retinoic acid and
all-trans retinoic acid was suppressed, and tissue and
blood levels of resistin were decreased (32).
Similar to our results in acne patients, Corbetta et al.
have reported that acitretin in psoriasis patients caused
a slight decrease in insulin sensitivity and a decrease in
resistin levels but did not affect adiponectin levels in
psoriatic patients and excluded the role of adipocytokines
in retinoid-induced insulin resistance (18) (Table 4).
Supporting their study, we have found a reduction in

resistin levels, despite the finding indicating that a fivemonth treatment of isotretinoin is related with insulin
resistance in our study. No other parameter was shown to
correlate with the change in resistin levels. Retinoids may
be involved in mechansims in decreasing resistin levels
directly by regulating resistin expression independently of
these parameters.
RBP4 is a recently defined protein that binds to
circulating retinol. RBP4 is thought be related to obesity,
insulin resistance, type-2 diabetes, and metabolic
syndrome (33) and is suggested to be an early indicator
of the development of insulin resistance and metabolic
syndrome, and that this adiponectin is more sensitive to
insulin than leptin, IL-6, and CRP (34). Our study suggests
that a 5-month treatment with isotretinoin increases the
mean RBP4 level in AV patients (P = 0.040) (Table 3).
However, there was no significant correlation between the
disease stage and pretreatment and posttreatment RBP4
levels. In addition, no significant correlation was observed
between age, pretreatment BMI, body fat mass, and lipid
levels, and the amount of change in RBP4 levels. Koistinen
et al. suggested that isotretinoin taken for 5 months caused
insulin resistance in AV patients, which was thought
to be related to RBP4 (7). Another study indicated that
isotretinoin treatment for three months did not affect
RBP4 levels (15) (Table 4). Considering the sensitivity of
RBP4 to show the insulin resistance, our study points out
that long-term treatment with isotretinoin increases the
insulin resistance in patients with AV.
In conclusion, our study suggests that isotretinoin
therapy in AV patients causes insulin resistance in these
patients regardless of age, BMI, body fat mass, and lipid
levels of these AV patients. Our study confirmed the effect
of isotretinoin on insulin resistance but lacked to point out
the parameters that affect the mechanism of this effect. The
limitations of our study are the low number of patients and
lack of long-term follow-up of patients after treatment.
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